Effects of Daytime Eszopiclone Administration in Shift Workers
Information source: Brigham and Women's Hospital
Information obtained from ClinicalTrials.gov on October 19, 2009 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Shift-Work Sleep Disorder
Intervention: eszopiclone (Drug); matching placebo (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Brigham and Women's Hospital Official(s) and/or principal investigator(s): Orfeu M Buxton, Ph.D., Principal Investigator, Affiliation: Brigham and Women's Hospital
Overall contact: Shawn P O'Connor, Phone: 617-525-6479
Summary
The purpose of this study is to test the effects of eszopiclone on daytime sleep and
overnight wakefulness in shift workers.
Clinical Details
Official title: Effects of Daytime Eszopiclone Administration in Shift Workers on Overnight Wakefulness During a Subsequent Simulated Nightshift
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Crossover Assignment, Efficacy Study
Primary outcome: Nighttime wakefulness assessed by mean sleep latency across 4 Maintenance of Wakefulness Tests
Secondary outcome: EEG-recorded sleep efficiencySubjective sleepiness and performance Objective vigilance task performance Sleep-dependent memory consolidation
Detailed description:
The current study seeks to extend the currently available treatments for SWSD by addressing
the putative root cause of the problem—the inability of night-shift workers with or without
SWSD— to obtain adequate daytime sleep in the face of the circadian drive for alertness that
increases across the biological day. Even healthy, young subjects who are sleep-deprived
overnight exhibit daytime sleep marked by frequent awakenings and low sleep efficiency, less
slow-wave sleep, and altered sleep architecture, e. g. earlier predominance of REM sleep.
Many night-workers routinely report 3-6 hours of habitual sleep duration for daytime sleep.
Pharmacological interventions to decrease awakenings and improve total sleep time during
daytime sleep could improve subsequent alertness during a night shift. Improving the
wakefulness of night-shift workers over the nighttime could result in substantial benefits
for the individual workers, improve workplace productivity and safety, and improve public
health.
Eligibility
Minimum age: 20 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age 20-50 (men or women)
- Current shift worker (for at least 3 months, at least 5 overnights/month and 3
consecutive)
- A willingness and ability to comply with study procedures
- If of child-bearing potential, using a medically-accepted method of birth control,
including abstinence, barrier method with spermicide, steroidal contraceptive (oral,
transdermal, implanted, or injected) in conjunction with a barrier method, or
intrauterine device [IUD]).
Exclusion Criteria:
- Current diagnosis of DSM-IV Axis I disorder (other than insomnia)
- Regular treatment (>1time/wk) with CNS-active medication within 1 month of first
inpatient visit
- Uncontrolled medical illness that would interfere with participation in the study
- BMI>32 or < 19. 8 kg/m2
- Current symptoms or diagnosis of any moderate to severe sleep disorder other than
SWSD
- Periodic Leg Movement of Sleep Index (PLMSi)>20/hr of sleep or Respiratory
Desaturation Index (RDI)>15 on polysomnography (PSG)
- Current alcohol or drug dependence/abuse
- Menopausal or peri-menopausal symptoms that disrupt sleep
- Pregnant, lactating, or planning to become pregnant
- Current smoking of more than 10 cigarettes per day
- Current use of over the counter sleep aids such as Benadryl or melatonin
Locations and Contacts
Shawn P O'Connor, Phone: 617-525-6479
Brigham & Women's Hospital, Boston, Massachusetts 02115, United States; Recruiting Orfeu M Buxton, Ph.D., Principal Investigator
Additional Information
Starting date: May 2009
Ending date: December 2009
Last updated: May 11, 2009
|